http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008103370-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-085 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-576 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2006-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2008103370-A |
| titleOfInvention | FIBROSIS MARKERS |
| abstract | 1. The use of a combination of at least two markers selected from uromodulin, MAC2 BP, AGP1 and cathepsin A for the detection of fibrotic changes in vitro. ! 2. Use according to claim 1, characterized in that it includes:! a) obtaining a biological sample and! b) measuring the concentration of these markers in this sample. ! 3. Use according to claim 2, characterized in that said biological sample is selected from blood, plasma and urine. ! 4. Use according to claim 2, characterized in that said biological sample is obtained from a mammal. ! 5. Use according to claim 2, characterized in that said biological sample is obtained from a man or a woman. ! 6. Use according to one of claims 1-5, further comprising comparing the marker levels with a reference value. ! 7. Use according to claim 6, characterized in that levels at least twice the control value are associated with the presence of fibrotic change. ! 8. Use according to claim 1, characterized in that said fibrotic change is selected from fibrosis of the lung, bone marrow, liver, pancreas, kidney, heart or multiple organs. ! 9. Use according to claim 1, wherein said fibrotic change is liver fibrosis. ! 10. Use according to claim 2, characterized in that the concentration of said marker is determined by a method selected from colorimetry, spectrophotometry, NMR, chromatography, electrophoresis, immunoassay, or a combination of these methods. ! 11. Use according to claim 1, characterized in that it comprises a combination of the three markers described in claim 1. ! 12. Use according to claim 1, characterized in that it comprises a combination of four markers: uromodulin, MAC2 BP, AGP1 and cathepsin� |
| priorityDate | 2005-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.